Payment overview · 2025
General Payments
$892.46
45 reported records · 7 companies
Healthcare provider profile · identity verified
Toby Andrew Hampton, M.D
Allopathic & Osteopathic Physicians|Family Medicine · JACKSON, TN · NPI 1831192699
Verified facts
What the public records show
CMS Open Payments records show Toby Andrew Hampton, M.D received $892.46 in general payments during 2025 across 45 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 58.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $525.45 | 58.9% | 20 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $185.88 | 20.8% | 17 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $63.57 | 7.1% | 3 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.62 | 4.7% | 2 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $40.66 | 4.6% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.84 | 2.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.44 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $892.46 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $525.45 | 20 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $185.88 | 17 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $41.62 | 2 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $40.66 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $40.66 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $37.55 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $26.02 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $26.02 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $14.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Tizanidine Hcl | Tizanidine Hcl | 301 | 87 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 248 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 213 | 57 |
| Meloxicam | Meloxicam | 178 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 136 | 46 |
| Atorvastatin Calcium | Atorvastatin Calcium | 130 | 40 |
| Lisinopril | Lisinopril | 125 | 38 |
| Gabapentin | Gabapentin | 123 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 122 | 17 |
| Promethazine Hcl | Promethazine Hcl | 106 | 25 |
| Metformin Hcl | Metformin Hcl | 100 | 40 |
| Potassium Chloride | Potassium Chloride | 97 | 31 |
| Levofloxacin | Levofloxacin | 94 | 64 |
| Buspirone Hcl | Buspirone Hcl | 93 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 93 | 26 |
| Furosemide | Furosemide | 91 | 26 |
| Mounjaro | Tirzepatide | 91 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 90 | 24 |
| Ibuprofen | Ibuprofen | 86 | 43 |
| Cefdinir | Cefdinir | 76 | 52 |
| Trazodone Hcl | Trazodone Hcl | 71 | 23 |
| Omeprazole | Omeprazole | 70 | 15 |
| Methylprednisolone | Methylprednisolone | 69 | 48 |
| Losartan Potassium | Losartan Potassium | 64 | 21 |
| Prednisone | Prednisone | 63 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 62 | 28 |
| Carvedilol | Carvedilol | 57 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 52 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 13 |
| Celecoxib | Celecoxib | 50 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 31 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 14 |
| Pregabalin | Pregabalin | 46 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 46 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 18 |
| Levothyroxine Sodium | Levothyroxine Sodium | 41 | 14 |
| Montelukast Sodium | Montelukast Sodium | 41 | 18 |
| Ozempic | Semaglutide | 41 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 40 | 12 |
| Fenofibrate | Fenofibrate | 40 | 12 |
| Mupirocin | Mupirocin | 40 | 15 |
| Spironolactone | Spironolactone | 39 | suppressed |
| Simvastatin | Simvastatin | 38 | 15 |
| Famotidine | Famotidine | 37 | 12 |
| Jardiance | Empagliflozin | 37 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 37 | suppressed |
| Eliquis | Apixaban | 36 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 31 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | 12 |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Allopurinol | Allopurinol | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Lyllana | Estradiol | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $892.46 · 45 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, KRYSTEXXA, NUZYRA, Natroba, OTEZLA, Qelbree, REPATHA, REXULTI, Spinosad, VRAYLAR, XHANCE | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error